10.8% Above Target

MBCN's consensus price target is $30, -10.8% below the current price of $33.65. The 3 analysts tracking MBCN see downside risk at present valuations.

MBCN has a consensus rating of "Hold" based on 3 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $30 implies -10.8% downside from current levels.

With a forward P/E of 14.0208x, MBCN trades at a relatively low valuation. The consensus target of $30 implies -10.8% move, suggesting the market may be pricing in risks.

The most bullish Wall Street analyst has a price target of $30 for MBCN, while the most conservative target is $30. The consensus of $30 represents the median expectation. Our quantitative valuation model projects a bull case target of $59 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

MBCN is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month MBCN stock forecast based on 3 Wall Street analysts shows a consensus price target of $30, with estimates ranging from $30 (bear case) to $30 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $45, with bear/bull scenarios of $28/$59.

Our quantitative valuation model calculates MBCN's fair value at $45 (base case), with a bear case of $28 and bull case of $59. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.

MBCN trades at a forward P/E ratio of 14.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 17.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Analysts are cautious on MBCN, with 0 Sell ratings and a price target of $30 (-10.8% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

MBCN analyst price targets range from $30 to $30, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $30 consensus represents the middle ground. Our model's $28-$59 range provides an independent fundamental perspective.